Designing and optimization of novel human LMTK3 inhibitors against breast cancer – a computational approach
- 8 April 2016
- journal article
- research article
- Published by Taylor & Francis in Journal of Receptors and Signal Transduction
- Vol. 37 (1) , 51-59
Abstract
Estrogen receptor-α (ERα) is expressed more in patients with breast cancer and its level correlated with endocrine resistance. LMTK3 is reported as breast cancer target with regulation of estrogen receptor-α (ERα) through phosphorylation. In this computational study, structure-based inhibitor screening was performed on human LMTK3 using ZINC database. ATP-binding cavity with critical residues involved in the LMTK3 phosphorylation was used as target site for the screening. From the large ligand library, the best compounds were screen with three-phase virtual screening methods in Dockblaster, AutoDock Vina and AutoDock, respectively. The evaluation of ligands was carried out by binding energy and weak interactions, such as hydrogen bond interactions and hydrophobic contacts, in the target site that favors LMTK3 inhibition. Top compounds were found to be more effective in druglikeness activity by ADME prediction. The stability and binding affinity of ligand complexes were optimized by trajectory analysis such as RMSD, Rg, SASA and interhydrogen bonds from molecular dynamics simulations. The behavior of protein motion after ligand binding was illustrated by eigenvectors from principal component analysis (PCA). In addition, binding free energy of the LMTK3–ligand complexes were calculated by MM/PBSA methods and results supported the strong binding in dynamic system. Thus, the computational studies illustrated the structural insights on LMTK3 inhibition mechanism by ligands ZINC04670539, ZINC05607079 and ZINC04344028, also proposed as potent lead candidates. Our findings step towards developing novel LMTK3 inhibitors and identified lead candidates can be future breast cancer drugs with further experimental studies.Keywords
This publication has 29 references indexed in Scilit:
- Lemur tyrosine kinase-3 (LMTK3) in cancer and evolutionOncotarget, 2011
- ERasing breast cancer resistance through the kinomeNature Medicine, 2011
- Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancerNature Medicine, 2011
- Retracted: CK1δ modulates the transcriptional activity of ERα via AIB1 in an estrogen-dependent manner and regulates ERα–AIB1 interactionsNucleic Acids Research, 2009
- Phosphorylation of Estrogen Receptor-α at Ser167 Is Indicative of Longer Disease-Free and Overall Survival in Breast Cancer PatientsClinical Cancer Research, 2007
- Protein Kinases as Targets for Cancer TreatmentPharmacogenomics, 2007
- Selective Phosphorylations of the SRC-3/AIB1 Coactivator Integrate Genomic Reponses to Multiple Cellular Signaling PathwaysMolecular Cell, 2004
- The protein tyrosine kinase family of the human genomeOncogene, 2000
- EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometriumThe Journal of Steroid Biochemistry and Molecular Biology, 1999
- Breast CancerNew England Journal of Medicine, 1992